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ABSTRACT 
 
Background: Kidney biopsy is frequently performed in our centre as an outpatient procedure. 
The aim of this study was to evaluate the safety of biopsy in the outpatient setting. 
Methods: We analysed kidney biopsies performed from March 2013 to February 2017. 725 
biopsies performed in the outpatient setting were identified: There were 592 transplant and 
133 native biopsies including 3 solitary kidney biopsies. All were performed under ultrasound 
guidance using a 16G or 18G needle, with freehand technique. In all patients with 
eGFR<30ml/min/1.73m2 desmopressin was administered. Patients were observed for 6h 
before discharge, with a CBC and urine test after 4h. Major complications were haemorrhage 
requiring therapeutic intervention or transfusion. Minor complications were significant 
reduction in Hb levels (>10%), without need for transfusion or intervention and 
macrohaematuria. 
Results: There were 506 (69.8%) male patients. Average age was 50.3 ±12.7 yrs. Indications 
for native kidney biopsy included nephrotic syndrome (39.8%), nephritic syndrome (42.9%), 
follow-up biopsy (15.8%), and other (1.5%). There were no major complications. A decline in 
Hb was observed in 72% of pts. Average Hb decline was 4.2±6.3 g/L. In 10.1% pts there was 
>10% reduction in Hb level, with no evident bleeding, including by ultrasonography. In 2.5% 
of patients macrohaematuria was present. In a multivariate analysis male gender, lower eGFR, 
higher prebiopsy Hb and native kidney biopsy were predictive for Hb decline. No therapeutic 
interventions were required. 
Conclusion: We found that kidney biopsy performed in an outpatient setting in select patients 
is only rarely associated with adverse events and is a safe procedure.  
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Abbreviation list 
 
AV fistula = arteriovenous fistula 
BW =body weight 
PRBC = packed red blood cells 
DDAVP= desmopressin 
G = gauge 
IV= intravenous 
AKI= acute kidney injury 
CKD= chronic kidney disease 
CT= computed tomography 
PT= prothrombin time 
APTT=activated partial thromboplastin time 
BW= body weight 
eGFR=estimated glomerular filtration rate 
US=ultrasound 
CBC=complete blood count 
Hb= haemoglobin 
 
 Introduction 
 
Kidney biopsy is an essential part in the diagnosis and management of parenchymal 
renal diseases.[1] Since its introduction in the 1950s [2] it remains the most exact diagnostic 
method for kidney parenchymal disease. It provides important information, altering treatment 
in a high percentage of cases [3]. The percutaneous kidney biopsy with real time ultrasound 
guidance is the current standard of care.[4,5,6] Complications include macrohaematuria, 
haematoma, AV fistula, bleeding or even nephrectomy. A systematic review and meta-
analysis of percutaneous kidney biopsies from 1980 to 2011 (which included 34 studies with 
9474 biopsies that had met the inclusion criteria) was performed by Corapi et al. [7] , the rates 
of complications in the review were ranging from 3.5% for macrohaematuria (CI 0.3 to 14.5), 
over PRBC transfusion in 0.9% (CI 0.4 to 1.5) to nephrectomy 0.01%. The rates of 
complications differ among centres. [8,9]  In recent reports using real-time ultrasound 
guidance, complication associated with excessive bleeding  rates are even more infrequent. 
[6,8,10]  
To avoid adverse events, risk assessment remains crucial. In a recent review [7], 
predictors of PRBC transfusion included the needle gauge (14 vs. 16 or 18), sex (female), 
serum creatinine (≥ 180μ/L), low haemoglobin prior biopsy (≤ 120 g/L), AKI, high blood 
pressure, haemostasis abnormalities and anatomical abnormalities – horseshoe kidney, 
solitary kidney. Similar findings were reported in some other studies.[9,11,12] A historical 
contraindication, solitary kidney is today no longer  reported as a contraindication in some 
centres. [13] As mentioned, the haemorrhagic diathesis present in uremic patients with 
advanced CKD is associated with higher risk for bleeding. Desmopressin (DDAVP) is the 
most common agent used to treat or prevent bleeding in uremic patients. [14,15] DDAVP 
improves haemostasis by releasing factor VIII:von Willebrand factor multimers from 
endothelial cells. Desmopressin reverses uremic platelet dysfunction quickly (circa within one 
hour of IV injection) for a short duration of time (around 24 h).[16] 
With a better safety profile and technological development, kidney biopsy is performed in 
some centres as an outpatient procedure. [4,17] In the outpatient setting it is important to 
know the timing of complications to determine the optimal post-biopsy observation period.  In 
a study form France [18] 100% of complications occurred in outpatients within 8 hours vs. 
72% complications in inpatients, and 10% of inpatients had complications >24h hours after 
biopsy.  Historical data, prior to real-time ultrasound guidance, advised for longer observation 
periods.[19]  
Another issue in renal biopsy is whether post biopsy imaging should be routine. In a 
recent review the utility of post-biopsy ultrasonography or CT has not been shown [4] . A 
presence of haematoma on post biopsy imaging does not predict clinically relevant 
complications, but the absence of haematoma has a high negative predictive value and 
imaging is proposed only when clinically needed. [4, 20-21]  
  In our centre biopsy is frequently performed as an outpatient procedure in suitable 
patients. We performed a retrospective observational study to evaluate the safety of biopsy in 
the outpatient setting. 
 
 Materials and Methods 
 
We analysed native and transplant kidney biopsies performed at University Hospital 
Merkur outpatient clinic from March 2013 to February 2017. 725 biopsies performed in the 
outpatient setting were identified. There were 592 biopsies in transplant patients, and 133 
native kidney biopsies, including 3 solitary kidney biopsies. On the day of the biopsy 
complete blood count, international normalized ratio/prothrombin time, activated partial 
thromboplastin time, serum creatinine, potassium and sodium were obtained. All medications 
which could increase bleeding risk (e.g. anticoagulants, antiplatelet agents, and nonsteroidal 
anti–inflammatory drugs) were omitted for an appropriate period prior to biopsy. Polycystic 
kidney disease, and radiological evidence of small atrophic kidneys were considered 
contraindications for biopsy. Abnormalities in haemostasis (prolonged PT, APTT, low platelet 
count) were contraindications for the procedure in the outpatient setting. Kidney function was 
determined using the 4-variable Modification of Diet in Renal Disease study equation to 
estimate glomerular filtration rate. [22] In all patients with eGFR<30-45 ml/min/1.73m2 
desmopressin (0.4 µg/kg BW IV) was administered prior to the procedure. All biopsies were 
performed under US guidance using a 16G or 18G automated, spring–loaded needle with 
freehand technique. Bed rest for 4 hours was prescribed to all patients. While on bed rest, a 
2-kilo sandbag was placed over (in kidney transplant patients) or under (native kidney) the 
biopsy site. Patients were observed for 6 h before discharge. A CBC and a urine test were 
performed after 4 hours. Ultrasonography was performed upon attending clinician discretion. 
All patients were told to visit the emergency room if they developed any symptoms including 
pain, increasing heart rate, dizziness, or fever after discharge. Study outcomes were major 
and minor complications. Major complications were defined as haemorrhage requiring 
therapeutic intervention to stop bleeding and/or packed red blood cell (PRBC) transfusion. 
Minor complications were defined as significant reduction in Hb levels (>10%), without need 
for PRBC transfusion and/or intervention to stop bleeding and macrohaematuria, without 
intervention to stop bleeding.  
 
Statistical analysis 
Statistical analysis was performed using Statistica v13.1 (Dell Software Inc, San 
Francisco, USA). A p<0.05 was considered to be significant. The data are expressed as the 
median and range, or mean with standard deviation, as appropriate. Categorical variables are 
presented as frequency counts and percentages. The categorical values were compared using 
χ2 test and continuous values between the two groups were compared using Student’s t-test, 
or Mann-Whitney test in case of not-normally distributed values. Correlations between the 
two continuous variables were tested by the Pearson correlation. A multiple regression 
analysis was performed to assess independent predictors of Hb decline. We included into 
multivariate analysis all variables that were associated with Hb decline in univariate analysis 
with p≤0.1. 
 Results  
 
There were 219 (30.2%) female and 506 (69.8%) male patients. Average age was 50.3 ±12.7 
yrs. Indications for native kidney biopsy included nephrotic syndrome (39.8%), nephritic 
syndrome (42.9%), follow-up biopsy (15.8%), and other (1.5%). From 592 transplant biopsies 
72.8% were indication and 27.2% were protocol biopsies. The study population 
characteristics can be seen in Table 1. The glomerular yield in 97.5% of biopsies was 
sufficient for analysis. A decrease in haemoglobin was observed in 72% of patients. Average 
haemoglobin decline postbiopsy was 4.2±6.3 g/L (3.4% ± 5.2%) (Table 1).  There were no 
major complications requiring an intervention to stop bleeding, or blood transfusion (Table 2). 
In 10.1% of patients there was >10% reduction in Hb level, with no evident bleeding, 
including by US. In 2.5% of the patients postbiopsy macrohaematuria was present, without 
requirement for intervention or blood transfusion. In 61.9% of patients the decrease in 
haemoglobin was less than 10%. In 28% of patients there was no haemoglobin decline after 
biopsy. Microhaematuria was present in 78.6% of patients. 11 patients (1.5%) were 
hospitalized for overnight monitoring; all were discharged the next day. There were no 
therapeutic interventions required for biopsy complications. All patients included in the 
study had multiple follow-up visits so we can be sure that there were no late 
complications. 
 
 The subgroup analysis between patients with native kidneys and transplanted is shown 
in the Table 3. Haemoglobin prior to biopsy, eGFR and the decline in haemoglobin were 
higher in the native kidney group ( p=0.02, p<0.001 and p=0.04 respectively). 
In univariate analysis age, eGFR, needle gauge and the number of passes were not predictive 
for post biopsy haemoglobin decline. Prebiopsy Hb (p=0.037), male sex (p=0.002) and native 
vs. transplant kidney biopsy (p=0.04) were predictive of decline (Table 4). The multivariate 
analysis is shown in Table 5.  
  
 Discussion 
 
We analysed the safety of outpatient native and transplant kidney biopsies in a large 
tertiary renal centre. University Hospital Merkur has the largest kidney biopsy volume in 
Croatia. In our outpatient biopsy cohort, no severe complications leading to an intervention, 
or to kidney loss were recorded during the period analysed. Complications that occurred were 
due to bleeding, similar as in other larger studies. [23,24] The paucity of complications in the 
study can be partially explained by a large proportion (81,6%) of transplanted kidney biopsy 
in our cohort, as evidenced from the Table 5. The anatomical localisation of the transplanted 
kidney makes them easier to visualise and to biopsy.   
A similar study of kidney allograft biopsies [25], showed a rate of complications of 1.8%, 
mostly comprising of mild complications (0.7%) and only 0.19% life-threatening 
complications. The difference in the study was that it comprised all allograft biopsies from the 
institution including inpatient biopsies and early post-transplant biopsies, although the 
majority were in outpatient biopsies. A favourable safety profile for outpatient kidney 
allograft biopsies was also reported from a paediatric study [26], with an incidence of adverse 
events 9.2%. A large majority of those were micro- and macroscopic haematuria (8.4%). 
 Our results are similar, with 2.5% complication rate for macroscopic haematuria, without the 
need for intervention. 10.1% experienced a decline in postbiopsy haemoglobin larger than 
10%, but also without the need for PRBC transfusion. Only one patient had prolonged local 
bleeding which resolved spontaneously. 
 All patients with eGFR of less than 30-45 ml/min/1.73 m2 received desmopressin to prevent 
bleeding, according to current recommendations in uremic patients. [14,15] We also 
employed strict control of coagulation parameters, and omitting of antiplatelet or 
anticoagulant agents for several days prior to biopsy. This is different from some other centres 
policies, where routine antiplatelet agent pause had not been routinely advocated. [27] A 
possible reason of a low incidence of complications overall may be the use of 16G and 18G 
(in a majority of our patients), instead of 14G needles, as described in other studies, thus 
minimising the bleeding risk.[7,9, 28-29] 
 
Our results show that outpatient biopsy, as performed in our centre is a safe procedure. 
Crucial to a good safety profile may be large centre volume, careful risk assessment prior to 
biopsy and the selection of lower risk patients for outpatient biopsy.   
Our study has limitations. This is a retrospective, single centre study. However, patient data 
and biopsy complications were prospectively recorded, minimising underreporting of 
complications. Nevertheless, for a definite conclusion about safety of outpatient kidney 
biopsy, a larger sample size and a multi-centre prospective study would be necessary. 
We found that kidney biopsy performed in an outpatient setting in select patients is only 
rarely associated with adverse events and is a safe procedure.   
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Tables 
 
 
Table 1  Study population characteristics (n=725) 
Native kidney; n (%) 133 (18.4) 
Transplanted kidney; n (%) 592 (81.6) 
surveillance 161 (27.8) 
indication 431 (72.8) 
Female; n (%) 219 (30.2) 
Age (years) 50.3 ±12.7 
Mean serum creatinine, µmol/L 150.3±67.8 (range 36 to 678) 
eGFR, ml/min/1.73m2 51.3±24.4  
Desmopressin 82 (11.3) 
Needle gauge   
16 18 (2.5) 
18 642 (88.6) 
N/A 65 (8.9) 
Number of passes (n=652) 2.1±0.7(range 1 to 7)  
Hb prebiopsy, g/L 124.4±19.8 (range 71 to 181) 
Hb postbiopsy, g/L  120.3±20.3 (range 71 to 186) 
Average Hb decline, g/L (%) 4.2±6.3 (3.4 ± 5.2) 
Data are presented as number (percentage), mean ± standard deviation, range. Haemoglobin (Hb), estimated glomerular 
filtration rate (eGFR).  
 
 
Table 2 Biopsy related complications (n=725) 
Macrohaematuria 18 (2.5) 
Reduction in Hb >10% 73 (10.1) 
Local haemorrhage  1 (0.1) 
Interventions  0 (0) 
Hospitalization 11 (1.5) 
Data are presented as number (percentage). 
 
 Table 3 Transplant vs native biopsies 
 
Transplant 
(n=592) 
Native 
(n=133) 
 
p 
 
Age, yrs 
 
50.6 ±12.1 49.3±15.2 0.31 
Male; n (%) 421(71%) 85(64%) 0.2 
Hb prebiopsy, g/L 
 
123.6±19.5 127.9±20.9 0.02 
Hb postbiopsy, g/L 
 
119.7±20.0 122.8±21.7 0.11 
ΔHb, g/L 
 
3.9±6.3 5.2±6.4 0.04 
Hb postbiopsy/  
Hb prebiopsy 
 
0.97±0.05 0.96±0.05 0.05 
eGFR, mL/min/1.73m2 
 
49.3±19.7 60.1±37.8 <0.001 
Data are presented as number (percentage), mean ± standard deviation. Haemoglobin (Hb), estimated glomerular filtration 
rate (eGFR). 
 
Table 4 Univariate analysis of Hb decline predictors 
 Mean ± SD p 
Sex (male vs. female) 4.67 ±6.16 vs. 3.06 ±6.62 0.002 
Transplant vs. native 3.94 ±6.29 vs. 5.21 ±6.42 0.04 
 R  
Age (per year) 0.062 0.098 
eGFR (per ml/min/1.73 m2) -0.064 0.087 
Hb prebiopsy (per g/L) 0.078 0.037 
No of passes -0.072 0.066 
Haemoglobin (Hb), estimated glomerular filtration rate (eGFR). Standard deviation (SD) 
 
Table 5 Multivariate analysis of Hb decline predictors 
 
delta Hb 
p 
 
delta Hb 
Beta (ß) 
 
-95.00% 
Cnf.Lmt 
 
+95.00% 
Cnf.Lmt 
 
Age (per year) 
 
0.162 0.059 -0.024 0.142 
Hb prebiopsy (per g/L) 
 
0.012 0.109 0.024 0.194 
eGFR (per ml/min/1.73 m2) 
 
0.043 -0.091 -0.179 -0.003 
Number of passes 
 
0.027 -0.087 -0.164 -0.010 
Sex (M) 
 
0.039 0.084 0.004 0.164 
Type (transplant) 
 
0.002 -0.124 -0.201 -0.046 
Haemoglobin (Hb), estimated glomerular filtration rate (eGFR), male sex (M). 
 
 
 
